Volume 1.23 | Jun 22

Hematopoiesis News 1.23, June 22, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Blood Deficiencies are Strong Predictors of Poor Outcome
For healthcare professionals diagnosing primary Sjogren’s Syndrome, the incidence of blood based deficiencies is the strongest predictor of a poor outcome in patients according to the results of a study. [Press release from EurekAlert! discussing research presented at the Annual Congress of the European League Against Rheumatism (EULAR 2010)]

The most published medium for hematopoietic CFC assays

by STEMCELL Technologies


Cord Blood Transplants A Viable Option In Leukemia
Researchers report findings that cord blood transplants are just as effective as bone marrow transplants for adult leukemia patients. [Press release from the Medical College of Wisconsin discussing online prepublication in Lancet Oncology]

Clinical Trial of Gene Therapy for AIDS-Related Lymphoma Shows Promising Results Against Cancer and HIV Infection
In the investigational therapy, patients underwent autologous hematopoietic cell transplantation in which their own blood stem cells were harvested and genetically engineered with three anti-HIV ribonucleic acids that block HIV from infecting new cells. [Press release from the City of Hope discussing online prepublication in Science Translational Medicine]

Specific Blood-Derived Cells Promote Survival in Heart Attack Model
A research team from McGill University report a beneficial effect on cardiac function in mouse models when implanted monocytes helped preserve cardiac function following a heart attack. [Press release from EurekAlert! discussing online prepublication in Cell Transplantation]

Need to expand CD34+ cells?
StemSpan® serum-free expansion media are optimized for expanding hematopoietic stem and progenitor cells

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Revised Map of the Human Progenitor Hierarchy Shows the Origin of Macrophages and Dendritic Cells in Early Lymphoid Development
Here, researchers provide a comprehensive analysis of the human hematopoietic hierarchy by clonally mapping the developmental potential of seven progenitor classes from neonatal cord blood and adult bone marrow. [Nat Immunol]

GSK-3 Promotes Conditional Association of CREB and Its Coactivators with MEIS1 to Facilitate HOX-Mediated Transcription and Oncogenesis
Researchers demonstrate here that GSK-3 maintains the MLL leukemia stem cell transcriptional program by promoting the conditional association of CREB and its coactivators TORC and CBP with homedomain protein MEIS1, a critical component of the MLL-subordinate program, which in turn facilitates HOX-mediated transcription and transformation. [Cancer Cell]

Immature B Cell Progenitors Survive Oncogenic Stress and Efficiently Initiate Ph+ B-Acute Lymphoblastic Leukemia
Researchers demonstrate that B cell progenitors up to and including the pro-B cell efficiently initiate Philadelphia chromosome positive (Ph+) B-acute lymphoblastic leukemia. [Blood]

Modeling the Human 8p11-Myeloproliferative Syndrome in Immunodeficient Mice
Here, researchers report that expression of ZMYM2/FGFR1 (previously known as ZNF198/FGFR1) or BCR/FGFR1 in normal human CD34+ cells from umbilical-cord blood leads to increased cellular proliferation and differentiation towards the erythroid lineage in vitro. [Blood]

In Vitro and In Vivo. Advantages Over Bone Marrow-Derived Mesenchymal Stem Cells” target=”_blank” href=”http://ajp.amjpathol.org/cgi/content/abstract/ajpath.2010.091042v1″ alias=”C08 Adipose Tissue-Derived Mesenchymal Stem Cells Facilitate Hematopoiesis In Vitro and In Vivo . Advantages Over Bone Marrow-Derived Mesenchymal Stem Cells” conversion=”false”>Adipose Tissue-Derived Mesenchymal Stem Cells Facilitate Hematopoiesis In Vitro and In Vivo. Advantages Over Bone Marrow-Derived Mesenchymal Stem Cells
In this study, researchers extensively evaluated the hematopoiesis-supporting properties of adipose tissue-derived mesenchymal stem cells, which are largely unknown. [Am J Pathol]


Effect of Graft Source on Unrelated Donor Hematopoietic Stem-Cell Transplantation in Adults with Acute Leukemia: A Retrospective Analysis
Researchers aimed to determine the optimal role of umbilical-cord blood grafts in transplantation for adults with acute leukemia, and to establish whether current graft-selection practices are appropriate. [Lancet Oncol]

Prognostic Impact of Monosomal Karyotype in Young Adult and Elderly Acute Myeloid Leukemia: The Southwest Oncology Group Experience
Monosomal Karyotype (MK), defined as two or more monosomies, or a single monosomy in the presence of structural abnormalities, has recently been reported as identifying a distinct subset of acute myeloid leukemia (AML) patients with an extremely poor prognosis. In an effort to confirm this observation, researchers analyzed the prognostic impact of MK in 1344 AML patients between the ages of 16 and 88 years treated on Southwest Oncology Group protocols. [Blood]

Monocyte Derivatives Promote Angiogenesis and Myocyte Survival in a Model of Myocardial Infarction
In this study, researchers have investigated the hypothesis that previously reported beneficial effect of peripheral blood mononuclear cells cultured under angiogenic conditions on cardiovascular function following ischemia is not limited to EPCs but also to monocytes contained therein. [Cell Transplant]

High Rate of Stem Cell Mobilization Failure after Thalidomide and Oral Cyclophosphamide Induction Therapy for Multiple Myeloma
The results demonstrate that the combination of thalidomide and oral cyclophosphamide impairs stem cell mobilization and indicate that drugs with no previously reported relevant effect on stem cell mobilization can have a substantial impact when given in combination. [Bone Marrow Transplant]


Lorus Therapeutics Announces Presentation of Phase II Clinical Trial Data for LOR-2040 in Acute Myeloid Leukemia
Lorus Therapeutics Inc. announced the presentation of Phase II clinical trial data for LOR-2040 (formerly known as GTI-2040) in combination with high dose cytarabine in the treatment of acute myeloid leukemia. [Lorus Therapeutics Inc. Press Release]

FDA Fines American Red Cross $16 Million for Prior Failures to Meet Blood Safety Laws
The FDA announced that the American Red Cross has been fined $16 million for prior failures to comply with Federal laws and regulations related to the collection and manufacture of blood products. [Food and Drug Administration, United States]

FDA Approves Tasigna® for Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demonstrate Major Advance Over Glivec®
Following a priority review, the U.S. Food and Drug Administration has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. [Novartis Oncology Press Release]

Medicare to Revisit Coverage of Anemia Drugs
The U.S. Centers for Medicare and Medicaid Services said it is reviewing its coverage of anemia drugs used to treat patients with kidney disease. [Reuters]

Micromet’s Cancer Missiles Lure Boehringer, Sanofi (Update2)
Micromet Inc., a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals. [Bloomberg Businessweek]


National Heart, Lung, and Blood Institute Funds Research to Improve Safety of Red Blood Cell Transfusions
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. [National Institutes of Health, United States]

New Videos Reveal How NIH Identifies the Most Promising Research Applications
The National Institutes of Health’s Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States]

NIH and Wellcome Trust Announce Partnership to Support Genomic, Population-Based Studies in Africa
The National Institutes of Health (NIH) and the Wellcome Trust announced a partnership with African researchers to conduct genetic and environmental studies in Africa of common, non-communicable disorders, such as heart disease and cancer, as well as communicable diseases, such as malaria. [National Institutes of Health, United States]

Notice of Intent to Publish a Funding Opportunity Announcement for the Centers Program for Research on HIV/AIDS and Mental Health (P30) (NOT-MH-10-022) [National Institutes of Health, United States]

Expanding and Personalizing Treatment Options for Alcohol Use Disorders Including Pharmacogenomics (R01) (PAS-10-215) [National Institutes of Health, United States]

Increased Budget Limit for Applications Submitted in Response to PAR-09-135, Replication, Fine-Mapping and Sequencing: Follow-Up on Genome-Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01) (NOT-AR-10-040) [National Institutes of Health, United States]

Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01) (PAR-10-216) [National Institutes of Health, United States]

July 26-27, 2010: Meeting of the Blood Products Advisory Committee Announcement [Food and Drug Administration, United States]


XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States

United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Update Profile  |  Contact Us